BR112017007224A2 - inibidores de canais de sódio, de peptídeo, aperfeiçoados - Google Patents

inibidores de canais de sódio, de peptídeo, aperfeiçoados

Info

Publication number
BR112017007224A2
BR112017007224A2 BR112017007224A BR112017007224A BR112017007224A2 BR 112017007224 A2 BR112017007224 A2 BR 112017007224A2 BR 112017007224 A BR112017007224 A BR 112017007224A BR 112017007224 A BR112017007224 A BR 112017007224A BR 112017007224 A2 BR112017007224 A2 BR 112017007224A2
Authority
BR
Brazil
Prior art keywords
sodium
improved
sodium channel
channel inhibitors
channels
Prior art date
Application number
BR112017007224A
Other languages
English (en)
Inventor
j christensen Dale
Tarran Robert
Original Assignee
Spyryx Biosciences Inc
Univ North Carolina Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spyryx Biosciences Inc, Univ North Carolina Chapel Hill filed Critical Spyryx Biosciences Inc
Publication of BR112017007224A2 publication Critical patent/BR112017007224A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Abstract

a presente invenção refere-se à capacidade de peptídeos, de ocorrência não natural, especializados, de se ligar a canais de sódio e inibir a ativação dos canais de sódio. a invenção refere-se, além disso, a métodos para a regulação de absorção de sódio e de volume de fluido e o tratamento de desordens responsáveis pela modulação de absorção de sódio pela modulação da ligação de peptídeos de ocorrência não natural, especializados, a canais de sódio.
BR112017007224A 2014-10-08 2015-10-08 inibidores de canais de sódio, de peptídeo, aperfeiçoados BR112017007224A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462061461P 2014-10-08 2014-10-08
PCT/US2015/054693 WO2016057795A1 (en) 2014-10-08 2015-10-08 Improved peptide inhibitors of sodium channels

Publications (1)

Publication Number Publication Date
BR112017007224A2 true BR112017007224A2 (pt) 2018-03-06

Family

ID=55653774

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017007224A BR112017007224A2 (pt) 2014-10-08 2015-10-08 inibidores de canais de sódio, de peptídeo, aperfeiçoados

Country Status (14)

Country Link
US (4) US20160102121A1 (pt)
EP (1) EP3204029A4 (pt)
JP (1) JP2017536334A (pt)
KR (1) KR20170083530A (pt)
CN (1) CN107206046A (pt)
AU (1) AU2015330895A1 (pt)
BR (1) BR112017007224A2 (pt)
CA (1) CA2963142A1 (pt)
IL (1) IL251016A0 (pt)
MX (1) MX2017004653A (pt)
PH (1) PH12017500613A1 (pt)
RU (1) RU2017115994A (pt)
SG (1) SG11201702769QA (pt)
WO (1) WO2016057795A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200031866A1 (en) * 2016-09-29 2020-01-30 Spyryx Biosciences, Inc. Peptide inhibitors of sodium channels
WO2018111903A1 (en) 2016-12-13 2018-06-21 Spyryx Biociences, Inc. Saline formulations of splunc1 peptides
WO2019067887A1 (en) * 2017-09-29 2019-04-04 Spyryx Biosciences, Inc. ENAC INHIBITOR PEPTIDES AND USES THEREOF

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW432305B (en) * 1997-03-31 2001-05-01 Hitachi Ltd Electronic commerce transaction system
US7384910B2 (en) 1997-10-08 2008-06-10 Castillo Gerardo M Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
WO2005056045A1 (en) 2003-12-04 2005-06-23 The University Of Iowa Research Foundation Methods and compositions related to plunc polypeptides
AU2005282028B2 (en) * 2004-09-10 2011-03-24 Newron Pharmaceuticals S.P.A. (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators
WO2006045710A2 (en) * 2004-10-27 2006-05-04 Novo Nordisk A/S Insulin receptor binding peptides with non-insulin gene activation profiles and uses thereof
US20080312093A1 (en) 2005-11-04 2008-12-18 Johji Inazawa Method for detecting cancer and a method for suppressing cancer
US7951781B2 (en) 2006-11-02 2011-05-31 University Of Iowa Research Foundation Methods and compositions related to PLUNC surfactant polypeptides
CL2008003651A1 (es) * 2007-12-10 2009-06-19 Novartis Ag Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
WO2010138794A2 (en) * 2009-05-29 2010-12-02 The University Of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins
JP6158097B2 (ja) 2011-03-18 2017-07-05 デューク・ユニヴァーシティ 炎症を抑制するためのペプチド
ES2716723T3 (es) 2011-09-20 2019-06-14 Univ North Carolina Chapel Hill Regulación de los canales de sodio por las proteínas PLUNC
WO2013108193A1 (en) * 2012-01-16 2013-07-25 Atox Bio Ltd. Synthetic peptides for treatment of bacterial infections

Also Published As

Publication number Publication date
US9796768B2 (en) 2017-10-24
CA2963142A1 (en) 2016-04-14
AU2015330895A1 (en) 2017-03-30
RU2017115994A (ru) 2018-11-12
US20170327538A1 (en) 2017-11-16
IL251016A0 (en) 2017-04-30
CN107206046A (zh) 2017-09-26
US10150796B2 (en) 2018-12-11
KR20170083530A (ko) 2017-07-18
US20190071468A1 (en) 2019-03-07
EP3204029A1 (en) 2017-08-16
US20170226180A1 (en) 2017-08-10
US20160102121A1 (en) 2016-04-14
WO2016057795A1 (en) 2016-04-14
MX2017004653A (es) 2017-10-16
PH12017500613A1 (en) 2017-09-04
RU2017115994A3 (pt) 2019-03-01
EP3204029A4 (en) 2018-07-11
JP2017536334A (ja) 2017-12-07
SG11201702769QA (en) 2017-05-30

Similar Documents

Publication Publication Date Title
EA201992497A1 (ru) МОДУЛЯТОРЫ K-Ras
BR112018073384A2 (pt) polinucleotídeos moduladores
EA201891057A1 (ru) Композиции и способы для ингибирования активности аргиназы
NI201800044A (es) Anticuerpos agonísticos que se unen específicamente a cd40 humano y métodos de uso
PE20171067A1 (es) Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
EA201792414A1 (ru) Антитела против cd166, активируемые антитела против cd166 и способы их применения
EA201792546A1 (ru) Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
DK3071709T3 (da) Mikrobiotasammensætning som en markør for modtagelighed over for kemoterapi og anvendelse af mikrobielle modulatorer (præ-, pro- eller synbiotika) til forbedring af virkningsgraden af en cancerbehandling
EA033325B1 (ru) Ингибиторы бромодомена
BR112017023821A2 (pt) moduladores de k-ras
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA201791773A1 (ru) Цистеиновая протеаза
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
EP3515472A4 (en) MODULATION OF REACTIONS ON CHECKPOINT INHIBITOR THERAPY
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
BR112019010131A2 (pt) entrega transdérmica de agentes grandes
EA201690708A1 (ru) Ингибиторы erk и способы применения
BR112016018313A2 (pt) moléculas de ligação multiespecíficas iga
BR112017000303A2 (pt) métodos para o tratamento de hipotensão
BR112018012304A2 (pt) composições e métodos para diminuir expressão de tau
EA201891299A1 (ru) Терапевтические антитела к cd9
BR112017007224A2 (pt) inibidores de canais de sódio, de peptídeo, aperfeiçoados
BR112018005331A2 (pt) inibidores de pcna

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements